How to Value a Medical Billing Company in 2026

Medical billing companies — or revenue cycle management (RCM) firms, as the industry prefers to call them — are among the most attractive acquisition targets in healthcare services right now. The revenue model is recurring, client switching costs are high, and the complexity of healthcare reimbursement means demand isn't going away. If anything, it's intensifying as coding requirements, prior authorization rules, and payer complexity continue to escalate.

I've worked on a number of these transactions, and the valuation spread is wide — anywhere from 5x to 10x EBITDAdepending on the business model, technology infrastructure, and client concentration. Understanding what separates a 5x company from a 10x company is critical whether you're buying, selling, or building.

The Revenue Model: Why Recurring Fees Drive Premiums

Medical billing companies typically generate revenue in one of three ways: percentage-of-collections (4-9% of what they collect for the client), flat per-claim fees ($3-$8 per claim), or monthly retainers based on provider count or practice size. Many companies use a hybrid model.

From a valuation perspective, the percentage-of-collections modelis the most attractive because it aligns the billing company's revenue with the client's success. As the practice grows, the billing company's revenue grows without renegotiation. It also creates a natural recurring revenue stream that is highly predictable month-to-month — exactly the kind of revenue profile that commands premium multiples.

Per-claim models are slightly less attractive because they don't capture the upside of client growth as directly, but they're still recurring and predictable. Monthly retainers provide the most stable revenue but can be harder to scale.

The companies that command the highest multiples have 85%+ of revenue from recurring sources— whether that's percentage-of-collections or contracted monthly fees. Project-based revenue (system implementations, consulting engagements) is valued at lower multiples because it requires continuous re-selling.

Valuation Multiples: The 5-10x Range

The range is wide, but it's not arbitrary. Here's how I think about where a medical billing company falls:

• 5-6x EBITDA: Small, people-dependent operations ($1-3M revenue). Limited technology, manual processes, owner handles key client relationships, concentrated client base.
• 6-8x EBITDA: Mid-size firms ($3-10M revenue) with established processes, some technology infrastructure, diversified client base, and a management layer beyond the owner.
• 8-10x EBITDA: Technology-enabled platforms ($10M+ revenue) with proprietary or deeply integrated software, strong client retention, diversified across specialties and geographies, and scalable operations.
• 10x+ EBITDA: True technology platforms with SaaS-like characteristics — proprietary RCM software, AI-driven automation, large client bases, and demonstrated ability to scale without proportional headcount growth.

The buyer pool shifts as you move up the scale. At 5-6x, you're selling to individual buyers or small PE firms. At 8-10x, the buyers are PE-backed RCM platforms executing roll-up strategies — companies like Ensemble Health Partners, Conifer Health, or the dozens of PE-backed platforms that have emerged in the last five years. At 10x+, you're potentially attracting strategic buyers like health systems or large technology companies entering the healthcare space.

Client Retention: The Most Important Metric

If I could only look at one metric to value a medical billing company, it would be net revenue retention — how much revenue you retain from your existing client base year-over-year, including expansion from growing practices and losses from churned clients.

The best medical billing companies achieve 95-100%+ net revenue retention. That means for every dollar of revenue they had last year from existing clients, they have 95 cents to a dollar this year — before any new client acquisition. The "100%+" happens when practice growth (and the corresponding revenue increase from percentage-of-collections models) outpaces any client losses.

Switching billing companies is painful — migrating AR, retraining staff, potentially changing PMS systems, and accepting 2-3 months of disrupted cash flow. Most practices won't switch unless the relationship is truly broken, which is why retention rates are naturally high.

Buyers analyze retention in detail. They'll want to see a client-by-client revenue history for at least three years. They'll ask about every client you've lost, why they left, and whether there are any clients at risk of leaving. A company with 97% retention and 10-year average client tenure is a fundamentally different asset than one with 85% retention and clients that churn every 3-4 years.

Technology Platform: What Separates Good from Great

The medical billing industry is in the middle of a technology transformation. The old model — teams of billers manually entering claims, following up on denials by phone, and posting payments from paper EOBs — is being replaced by automated platforms that use AI and machine learning to handle much of the workflow.

Buyers evaluate the technology stack closely:

• Claim scrubbing automation: Does the system catch coding errors before submission? Automated scrubbing reduces denial rates from 8-12% to 2-4%.
• Denial management workflow: Is denial follow-up systematized and tracked, or does it depend on individual biller knowledge?
• Payer integration: Does the platform have electronic connections to major payers for real-time eligibility verification, claim status checks, and ERA posting?
• Client-facing dashboards: Can clients see their revenue cycle metrics in real time, or do they wait for monthly reports?
• Scalability: Can the platform handle 2-3x current volume without proportional staff additions?

Companies with proprietary technology platforms or deep integrations with major practice management systems (Epic, Athenahealth, AdvancedMD, eClinicalWorks) trade at the top of the range. They're valued more like technology companies than services companies because the platform creates leverage — revenue can grow faster than headcount.

Client Concentration: The Value Killer

Client concentration is the single most common reason medical billing companies sell at the low end of the range. If your top client represents 25%+ of revenue, buyers see a business that's one contract cancellation away from a serious problem.

The ideal profile is no single client above 10% of revenueand the top 5 clients representing less than 35% combined. That level of diversification tells buyers that losing any single client won't materially affect the business.

Specialty concentration is a related risk — a company serving only orthopedic practices is exposed to specialty-specific reimbursement changes. I worked on a deal where a $4M billing company had strong operations but one client at 32% of revenue. The buyer offered 5.5x instead of the 7-8x the operations warranted, structuring an earn-out tied to retaining that client for 24 months. The concentration cost the seller roughly $1.5M in upfront value.

Compliance: The Non-Negotiable

Medical billing companies handle protected health information (PHI) for every patient whose claim they process. HIPAA compliance isn't optional — it's a deal requirement. Buyers will audit your compliance program as part of due diligence, and gaps can delay or derail transactions.

What buyers expect to see:

• Current HIPAA risk assessment (updated annually)
• Written policies and procedures for PHI handling
• Business Associate Agreements (BAAs) with all clients and subcontractors
• Employee training documentation
• Incident response plan and breach notification procedures
• SOC 2 Type II audit (increasingly expected for mid-size and larger companies)

Beyond HIPAA, buyers evaluate False Claims Act exposure. Any history of OIG investigations, qui tam lawsuits, or Medicare overpayment demands is a serious red flag that can result in large escrow holdbacks or deal termination.

Positioning for a Premium Exit

If you're running a medical billing company and thinking about selling, the playbook is straightforward but requires lead time:

Diversify your client base. If you have concentration risk, the fastest way to address it is to win new clients in different specialties and geographies. Two years of client diversification effort can add 1-2 turns to your multiple.

Invest in technology. If your operation is still heavily manual, begin automating claim scrubbing, denial management, and payment posting. Even adopting third-party RCM technology (rather than building your own) demonstrates a commitment to scalability that buyers value.

Lock in contracts. Move clients from month-to-month to 2-3 year contracts. Long-term contracts give buyers revenue visibility and reduce churn risk.

Get compliant and build depth. If you don't have a current HIPAA risk assessment, do it now. If you can afford SOC 2, do that too. And if you're the person clients call when there's a problem, hire or promote a client services leader who can own those relationships before going to market.

The Bottom Line

Medical billing companies sit at the intersection of healthcare's complexity and the recurring revenue model that buyers love. The 5-10x EBITDA range is wide, but the path from the low end to the high end is clear: diversify clients, invest in technology, maintain bulletproof compliance, and build an organization that doesn't depend on any single person — including you. The companies that do those things aren't just worth more today; they're positioned to capture the growing demand for outsourced revenue cycle management as healthcare reimbursement continues to get more complex.